|
US2021113511A1
|
|
Methods and compositions for the treatment of acne
|
|
WO2021059281A1
|
|
Treatment of skin disorders with topical combination compositions comprising tapinarof and an additional ahr activator
|
|
WO2021059283A1
|
|
Treatment of cutaneous adverse effects caused by oncological therapy with topical tapinarof compositions
|
|
US2020390725A1
|
|
Treatment of ocular diseases with ophthalmic tapinarof compositions
|
|
WO2021014447A1
|
|
Treatment of skin disorders with topical tapinarof-egfr inhibitor compositions
|
|
WO2021014453A1
|
|
Topical jak inhibitor combination compositions for treatment of inflammatory skin conditions
|
|
US2020390724A1
|
|
Treatment of ocular diseases with ophthalmic tapinarof compositions
|
|
WO2020255135A1
|
|
Treatment of ocular inflammatory diseases with topical ophthalmic tapinarof compositions
|
|
WO2020212982A1
|
|
Treatment of gastrointestinal disorders with rectal tapinarof compositions
|
|
WO2020194313A1
|
|
Treatment of hidradenitis suppurativa with tapinarof compositions
|
|
WO2020188578A1
|
|
Combination of minocycline and benzoyl peroxide and method of use thereof
|
|
WO2020188575A1
|
|
Treatment of rosacea with topical combination compositions
|
|
WO2020174467A1
|
|
Treatment of psoriasis with topical tapinarof- tazarotene combination compositions
|
|
WO2020152690A1
|
|
Treatment of skin disorders with topical tapinarof combination compositions
|
|
US2020197397A1
|
|
Treatment of skin disorders with compositions comprising an egfr inhibitor
|
|
WO2020136650A1
|
|
Treatment of skin disorders with compositions comprising an egfr inhibitor
|
|
WO2020089891A1
|
|
Topical minocycline foamable compositions
|
|
WO2020044344A1
|
|
Compositions comprising ozenoxacin
|
|
US2019240149A1
|
|
Pharmaceutical compositions comprising silica microspheres
|
|
US2018339176A1
|
|
Core stabilized microcapsules, method of their preparation and uses thereof
|
